Race Oncology Ltd. ( (AU:RAC) ) has issued an announcement.
Race Oncology Ltd has announced the activation of the Southside Cancer Care Centre in Miranda, NSW, as the first Australian site for its Phase 1 clinical trial of RC220 in combination with doxorubicin for advanced solid tumors. This trial aims to gather safety, tolerability, and pharmacokinetic data, and assess the maximum tolerated dose and potential anticancer efficacy of RC220. The trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, using a Bayesian design for greater flexibility. This development marks a significant step in Race Oncology’s efforts to advance RC220 as a promising cancer treatment, potentially improving therapy outcomes while reducing side effects for patients.
More about Race Oncology Ltd.
Race Oncology Ltd is a company operating in the biotechnology industry, focusing on the development of cancer therapies. Their primary product, RC220, is an anticancer agent designed to enhance the effectiveness of existing treatments like doxorubicin while minimizing side effects. The company is actively involved in clinical trials to evaluate the safety and efficacy of its products, with a market focus on advanced solid tumors.
YTD Price Performance: -14.81%
Average Trading Volume: 92,847
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$185M
For an in-depth examination of RAC stock, go to TipRanks’ Stock Analysis page.